Back

Pembrolizumab plus anthracyclines in triple-negative breast cancer: prospective evaluation of early cardiac safety

19 June 2026 (10:45 - 11:30)
Organised by: Logo
Congress Presentation Part of: From exposure to events: cardiovascular risk in cancer care Diagnosis and Management of Cardiovascular Disease in Patients with Cancer Delegates Premium Access ESC Cardio-Oncology 2026 Council of Cardio-Oncology

About the speaker

Photo
Miss Audrey Besnard

ICO, Angers (France)

4 More presentations in this session

Presentation thumbnail
Baseline cardiovascular assessment and incidence of major adverse cardiovascular events during immune checkpoint inhibitor therapy in a hungarian population
Doctor Z. Drobni (Budapest, HU)
Abstract Slides
Presentation thumbnail
The myocardial effects of proton vs. photon radiotherapy in left-sided breast cancer patients: a cardiac MRI study
Doctor V. Juhasz (Boston, US)
Abstract Slides
Presentation thumbnail
X-ray irradiation of the apex of the heart affects cardiac function by modulating the sympathetic nervous system and calcium transients
Doctor V. Monceau (Fontenay-aux-Roses, FR)
Abstract Slides
Presentation thumbnail
Non-fatal major cardiovascular events associated with androgen receptor pathway inhibitors in prostate cancer: systematic review and network meta-analysis
Associate Professor C. Dolladille (Caen, FR)
Abstract Slides

Access the full session

Session thumbnail
From exposure to events: cardiovascular risk in cancer care

The Event

Event poster

ESC Cardio-Oncology 2026

19 June 2026 10:45 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources